Loading...
•
Dec 31, 2020
Novocure Q4 2020 Earnings Report
Reported a 45 percent revenue increase compared to Q4 2019, driven by growth across all regions and advancements in clinical programs.
Key Takeaways
Novocure reported strong fourth-quarter results with a 45% increase in net revenues compared to Q4 2019. The company's financial strength positions it well to invest strategically in science and technology to further develop its Tumor Treating Fields platform.
Net revenues reached $144.0 million, a 45% increase compared to Q4 2019.
Net income was $4.9 million, with earnings per share of $0.05.
Active patients at the end of the period were 3,411, representing a 17% increase year-over-year.
Adjusted EBITDA increased by 101% to $34.8 million compared to Q4 2019.
Novocure
Novocure
Forward Guidance
Novocure anticipates several clinical milestones over the next few years.
Positive Outlook
- Final data from phase 2 pilot HEPANOVA trial in advanced liver cancer (Q2 2021)
- Interim analysis of phase 3 pivotal INNOVATE-3 trial in recurrent ovarian cancer (Q3 2021)
- Interim analysis of phase 3 pivotal LUNAR trial in non-small cell lung cancer (Q4 2021)
- Final data from phase 2 pilot EF-31 trial in gastric cancer (2022)
- Interim analysis of phase 3 pivotal PANOVA-3 trial in locally advanced pancreatic cancer (2022)
Challenges Ahead
- Final data from phase 3 pivotal METIS trial in brain metastases (2022)
- Final data from phase 2 pilot EF-33 trial with high-intensity arrays in recurrent glioblastoma (2022)
- Final data from phase 3 pivotal INNOVATE-3 trial in recurrent ovarian cancer (2023)
- Final data from phase 3 pivotal LUNAR trial in non-small cell lung cancer (2023)
- Final data from phase 3 pivotal PANOVA-3 trial in locally advanced pancreatic cancer (2023)